Damora Therapeutics is trading 7.6% up at $29.62 on investor positioning ahead of pipeline milestones, rebounding from the previous session's 8.23% decline.
- Traders are focused on the DMR-001 regulatory timeline, with the company's first submission on track for mid-2026.
- Market sentiment is further supported by a strong balance sheet, with a cash runway currently extending into 2029.